Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2013 Financial Results on May 7, 2013

  Seattle Genetics to Host Conference Call and Webcast Discussion of First
  Quarter 2013 Financial Results on May 7, 2013

Business Wire

BOTHELL, Wash. -- April 18, 2013

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its
first quarter 2013 financial results on Tuesday, May 7, 2013, after the close
of financial markets. Following the announcement, company management will host
a conference call and webcast discussion of the results and provide a general
corporate update. Access to the event can be obtained as follows:

LIVE access on Tuesday, May 7, 2013
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  *Telephone (877) 941-0843 (domestic) or (480) 629-9866 (international);
    conference ID 4614604
  *Webcast available at http://www.seattlegenetics.com/ in the Investors and
    News section

REPLAY access

  *Telephone replay will be available beginning at approximately 3:30 p.m. PT
    on Tuesday, May 7, 2013 through 5:00 p.m. PT on Thursday, May 9, 2013 by
    calling 800-406-7325 (domestic) or 303-590-3030 (international);
    conference ID 4614604
  *Webcast replay will be available on the Seattle Genetics website at
    http://www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and
commercialization of monoclonal antibody-based therapies for the treatment of
cancer. The company’s lead program, ADCETRIS^® (brentuximab vedotin), received
accelerated approval from the U.S. Food and Drug Administration in August 2011
and approval with conditions from Health Canada in February 2013 for two
indications. In addition, under a collaboration with Millennium: The Takeda
Oncology Company, ADCETRIS received conditional marketing authorization from
the European Commission in October 2012. Seattle Genetics also has four other
clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle
Genetics has collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including Abbott, Agensys (an
affiliate of Astellas), Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC
co-development agreements with Agensys and Genmab. More information can be
found at www.seattlegenetics.com.

Contact:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com